Renal Anemia Market Report and Forecast 2025-2034

The renal anemia market was valued at USD 4.91 Billion in 2024, driven by the increasing prevalence of chronic kidney disease across the 8 major markets. The market is expected to grow at a CAGR of 7.50% during the forecast period of 2025-2034, with the values likely to reach USD 10.12 Billion by 2034 .

Renal Anemia Market Overview

Renal anemia is a common complication of chronic kidney disease and is associated with significant morbidity and mortality. It occurs in over 90% of patients receiving renal replacement therapy. Renal anemia is primarily caused by a reduction in erythropoietin production in the kidneys. The market for renal anemia is driven by the increasing prevalence of chronic kidney disease and the growing aging population. The rising adoption of novel therapies such as hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) and the shift towards combination therapies are major trends poised to support market growth. Moreover, innovations in iron supplementation methods, the expansion of healthcare infrastructure, and rising diagnosis rates are some of the factors projected to shape the market landscape.

Renal Anemia Market Growth Drivers

Increasing Prevalence of Chronic Kidney Disease to Drive Market Growth

Recent data suggests that the global prevalence of chronic kidney disease (CKD) is around 13.4% (11.7-15.1%). Anemia is a common complication of chronic kidney disease and is linked with CKD progression, cognitive impairment, increased risk of hospitalization, and reduced quality of life, among others. The prevalence of anemia in chronic kidney disease varies across regions, with around 500,000 adult patients on dialysis affected by anemia due to chronic kidney disease in the United States. Thus, the rising burden of chronic kidney disease is one of the primary drivers of the market.

Renal Anemia Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Rise in Drug Approvals to Affect the Market Landscape Significantly

In March 2024, Akebia Therapeutics Inc., a United States-based fully integrated renal biopharmaceutical company announced that its Vafseo (vadadustat) tablets, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, received approval from the US Food and Drug Administration (FDA) for the treatment of anemia in chronic kidney disease adult patients who have been on dialysis for at least 3 months. The surge in new drug approvals by regulatory bodies is poised to fuel the market growth in the forecast period.

Development of Alternative Iron Supplementation Methods Poised to Augment Renal Anemia Market Demand

One of the major market trends is the increasing innovations in iron supplementation methods which is poised to boost the market demand. The development of new formulations of intravenous (IV) iron that exhibit longer durations of action, and enhance iron absorption, and utilization are expected to improve patient compliance and outcomes.

Increased Focus on Combination Therapies to Elevate the Renal Anemia Market Value

The market is experiencing a growing adoption of combination therapies for managing renal anemia, where multiple drugs or treatment types are prescribed together to achieve optimal outcomes. For instance, combining erythropoiesis-stimulating agents (ESAs) with iron supplements or using hypoxia-inducible factor prolyl hydroxylase inhibitors in combination with other therapies can provide better results in the management of renal anemia.

Shift Towards Novel Therapies to Boost Renal Anemia Market Size

The growing preference for novel therapies such as hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in place of traditional treatments like erythropoiesis-stimulating agents (ESAs) is a significant market trend. HIF-PHIs work by triggering the body’s natural response to low oxygen levels, thereby promoting erythropoiesis without risks linked with high doses of ESAs.

Renal Anemia Market Segmentation

Renal Anemia Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

• Iron Deficiency Anemia
• Vitamin B12 Deficiency Anemia
• Folate Deficiency Anemia
• Aplastic Anemia
• Sickle Cell Anemia
• Others

Market Breakup by Treatment Type

• Iron Supplements
• Erythropoiesis-stimulating Agents (ESAs)
• Vitamin B12 Supplements
• Transfusion Therapy
• Bone Marrow Transplant
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by End-user

• Hospitals & Clinics
• Homecare Settings
• Dialysis Centers
• Others

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

Renal Anemia Market Share

Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth

The market segmentation based on treatment type includes iron supplements, erythropoiesis-stimulating agents (ESAs), vitamin B12 supplements, transfusion therapy, bone marrow transplant, and others. Erythropoiesis-stimulating agents (ESAs) are commonly used in the treatment of renal anemia. They are known to stimulate the bone marrow to produce more red blood cells and are widely used in both dialysis and non-dialysis patients. ESAs are typically administered via injection and are reported to reduce the need for blood transfusions in chronic kidney disease patients.

Renal Anemia Market Analysis by Region

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is a leading market for renal anemia owing to the high prevalence of chronic kidney and a growing aging population. The easy access to innovative treatments like erythropoiesis-stimulating agents (ESAs) and hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in the country further supports the market growth. Moreover, the robust regulatory support from health authorities like the FDA and ongoing research and development efforts to improve therapeutic options for renal anemia is anticipated to aid the market expansion in the region in the forecast period.

Leading Players in the Renal Anemia Market

The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

AstraZeneca

AstraZeneca, a major pharmaceutical and biotechnology company, is headquartered in Cambridge, United Kingdom. The company’s first-in-class orally administered small molecule, Roxadusta t is indicated for the treatment of anemia in chronic kidney disease patients on dialysis. Roxadustat has received regulatory approval in a number of countries including China and Japan.

GSK plc

This British multinational pharmaceutical and biotechnology company is one of the leading players in the market, known for its solutions in renal anemia management. In February 2023, GSK's Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), received approval from the US Food and Drug Administration (FDA) for the treatment of anemia of chronic kidney disease in adult patients on dialysis.

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche Ltd (Roche), a Swiss multinational holding healthcare company, has a prominent presence in the market and is known for its biologics and advanced pharmaceuticals that treat a variety of chronic conditions, including CKD-related anemia. One of its key products is Recormon® pre-filled syringes which are used for the treatment of renal anemia.

Astellas Pharma

Japanese multinational pharmaceutical company Astellas Pharma plays a significant role in the market and is focused on offering novel therapeutic options for anemia management in chronic kidney disease patients. Its drug Evrenzo® (generic name: roxadustat) is approved for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis in Japan.

Other key players in the market include Amgen Inc., Otsuka Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Limited, Sanofi, AbbVie Inc., and Pfizer.

Key Questions Answered in the Renal Anemia Market Report

• What was the renal anemia market value in 2024?
• What is the renal anemia market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What is market segmentation based on the type of renal anemia?
• What is the market breakup based on treatment type?
• What is the market breakup by the route of administration?
• Who are the major end users in the market?
• What are the major factors aiding the renal anemia market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• How do the prevalence and incidence of chronic kidney disease affect the market landscape?
• What are the major renal anemia market trends?
• How does the rise in the geriatric population impact the market size?
• Which type of renal anemia will dominate the market share?
• Which treatment type is expected to have a high market value in the coming years?
• Which route of administration will experience the highest demand in the market segment?
• Which end user is projected to contribute to the highest market growth?
• Who are the key players involved in the renal anemia market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.